[ACST] Acasti Pharma, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 14.14 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.33 Change: 0.17 (14.65%)
Ext. hours: Change: 0 (0%)

chart ACST

Refresh chart

Strongest Trends Summary For ACST

ACST is in the long-term down -98% below S&P in 13 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Acasti Pharma Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of therapies for abnormalities in blood lipids, and the treatment and prevention of various cardiometabolic disorders in Canada and the United States. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trials for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding10.71 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities Gross Profit
Net Profit Operating Profit Total Assets Total Current Assets
Total Current Liabilities Total Debt Total Liabilities Total Revenue
Technical Data
High 52 week3.1 Low 52 week0.63 Last close0.71 Last change1.59%
RSI36.35 Average true range0.04 Beta0.3 Volume4.94 M
Simple moving average 20 days-2.49% Simple moving average 50 days-23.16% Simple moving average 200 days-39.8%
Performance Data
Performance Week7.92% Performance Month-34.26% Performance Quart-31.73% Performance Half-44.96%
Performance Year-43.2% Performance Year-to-date-24.69% Volatility daily6.55% Volatility weekly14.65%
Volatility monthly30.03% Volatility yearly104.04% Relative Volume5202.7% Average Volume196.58 K
New High New Low

News

2021-10-07 10:15:00 | Monteverde & Associates PC Filed A Class Action Lawsuit On Behalf Of Shareholders Of Acasti Pharma, Inc. In The Southern District Of New York

2021-10-06 08:30:00 | Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan

2021-09-27 08:30:00 | Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage

2021-09-22 08:30:00 | Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards

2021-09-14 08:30:00 | Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21??

2021-09-08 08:30:00 | Acasti Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

2021-08-31 14:27:54 | Why Shares of Acasti Pharma Slumped Tuesday

2021-08-27 08:40:00 | Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split

2021-08-25 07:02:41 | 21 Stocks Moving in Wednesday's Pre-Market Session

2021-08-12 07:00:00 | Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2022

2021-07-29 08:30:00 | Reminder: Acasti Pharma to Host Conference Call on August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics

2021-07-23 08:30:00 | Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM ET to Discuss Planned Acquisition of Grace Therapeutics

2021-07-07 09:00:00 | INVESTIGATION ALERT: Halper Sadeh LLP Investigates RAVN, SHSP, ICBK, ACST; Shareholders are Encouraged to Contact the Firm

2021-07-06 11:02:00 | SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Acasti Pharma Inc. Merger

2021-07-03 18:52:00 | INVESTIGATION ALERT: Halper Sadeh LLP Investigates ACST, CLDR, DISCA, GRA, TRMT, XEC; Shareholders are Encouraged to Contact the Firm

2021-07-03 00:14:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Acasti Pharma, Inc. - ACST

2021-06-24 03:22:05 | Acasti Pharma Inc.'s CVE:ACST Shift From Loss To Profit

2021-06-22 07:00:00 | Acasti Pharma Provides Fiscal 2021 Year-End Business Update

2021-06-14 16:20:40 | 10 Best Biotech Penny Stocks to Buy Now

2021-05-17 07:00:00 | Acasti Intends to Request Hearing Before Nasdaq Panel to Present Plan of Compliance

2021-05-13 18:05:00 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates UFS, FOE, CHMA, ACST; Shareholders are Encouraged to Contact the Firm

2021-05-12 17:31:00 | ACASTI PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Acasti Pharma Inc. - ACST

2021-05-07 11:53:48 | Acasti Pharma To Acquire Grace Therapeutics: Highlights

2021-05-07 11:14:00 | Acasti Pharma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Acasti Pharma Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ACST

2021-05-07 07:00:00 | Acasti Announces Definitive Agreement to Acquire Grace Therapeutics, Inc.

2021-03-08 17:30:00 | Acasti Pharma Provides Update on Recent Financing Activities

2021-02-09 06:55:00 | Acasti Pharma Announces Results for Third Quarter of Fiscal 2021

2021-01-27 06:55:00 | Acasti Pharma Provides Update on Recent Financing Activities

2020-12-25 12:00:05 | Acasti ACST Moves to Buy: Rationale Behind the Upgrade

2020-12-23 15:24:00 | Acasti Pharma Unaware of Any Material Change

2020-11-16 06:55:00 | Acasti Pharma Provides Business Update for the Second Quarter of Fiscal 2021

2020-11-12 05:43:52 | Here's Why Acasti Pharma CVE:ACST Must Use Its Cash Wisely

2020-10-01 16:30:00 | Acasti Pharma Announces the Election of Its Directors, Advisory Resolution Approving Compensation, Amendments to Its Stock Option and Equity Incentive Plans, Adoption of Amended & Restated General By-Law and Other Related Matters Approved at Its AGM

2020-09-29 06:55:00 | Acasti Announces Review Process of Strategic Alternatives

2020-09-16 06:55:00 | Acasti Appoints Seasoned Executive Brian D. Ford CPA-CA as Chief Financial Officer

2020-09-11 07:00:00 | Acasti Announces Filing and Mailing of Information Circular and Change in Record Date

2020-09-01 14:10:28 | Acasti Pharma Stock Loses a Wall Street Supporter

2020-08-31 07:00:00 | Acasti Pharma Reports Topline Triglyceride Results from Phase 3 TRILOGY 2 Study of CaPre in Patients with Severe Hypertriglyceridemia

2020-08-14 12:00:04 | What Makes Acasti ACST a New Buy Stock

2020-08-13 08:30:00 | Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021

2020-07-31 07:55:00 | Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains On Track to Report TRILOGY 2 Topline Data On or About August 31, 2020

2020-07-06 14:37:43 | Why Acasti Pharma's Stock Is Trading Higher Today

2020-06-29 09:45:12 | Acasti Pharma Provides Fiscal 2020 Year-End Business Update

2020-06-19 08:00:10 | Acasti Pharma Receives FDA Response to TRILOGY 1 Briefing Package

2020-06-04 21:49:01 | Hedge Funds Souring On Acasti Pharma Inc. ACST

2020-05-06 06:25:05 | Does The Acasti Pharma Inc. CVE:ACST Share Price Fall With The Market?

2020-04-30 08:30:10 | Acasti Pharma Announces Submission of TRILOGY 1 Briefing Package to FDA

2020-04-20 08:30:10 | Acasti Pharma Awarded Notice of Allowance for Second Composition of Matter Patent in Canada

2020-04-01 08:30:10 | Acasti Pharma Submits FDA Meeting Request on Schedule, and FDA Meeting Expected in the Second Half of June

2020-03-11 08:00:10 | Acasti Pharma Awarded Notice of Allowance for Additional Composition of Matter and Method of Use Patents in the United States and Mexico